The Food and Drug Administration (FDA) recently authorized a new formulation of ranitidine (formerly sold as Zantac) more than 5 years after the agency called for all versions of the drug to be withdrawn because of concerns that it could degrade into a carcinogenic compound. According to the agency, it has now approved VKT Pharma’s 150-mg and 300-mg ranitidine tablets after extensive safety testing and manufacturing improvements. There are also updated, more stringent storage instructions. …
Read More